|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...919293949596979899100101...156157» |
- Cosentyx (secukinumab) / Novartis
Trial termination: Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 26, 2014
P2, N=5, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; This study was terminated prematurely by the Sponsor for business reasons only.
- Cosentyx (secukinumab) / Novartis
Enrollment change, Trial termination: Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 26, 2014
P2, N=5, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; This study was terminated prematurely by the Sponsor for business reasons only. N=100 --> 5 | Recruiting --> Terminated; This study was terminated prematurely by the Sponsor for business reasons only.
- Clinical: T1REDEEM: Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=290, Not yet recruiting, Sponsor: University of California, San Francisco
- ||| New P1 trial: A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate (clinicaltrials.gov) - Jun 26, 2014
P1, N=58, Completed, Sponsor: Astellas Pharma Global Development, Inc.
- ||| Trial completion: A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate (clinicaltrials.gov) - Jun 26, 2014
P1, N=58, Completed, Sponsor: Astellas Pharma Global Development, Inc.
N=100 --> 5 | Recruiting --> Terminated; This study was terminated prematurely by the Sponsor for business reasons only. Not yet recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=44, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014
- |||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening (clinicaltrials.gov) - Jun 26, 2014
P4, N=320, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- ||| Orencia (abatacept) / BMS
P4 data: Post-marketing Study Assessing the Long-Term Safety of Abatacept (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=100000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- New P2 trial: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Jun 24, 2014
P2, N=50, Not yet recruiting, Sponsor: Department of Veterans Affairs
- Enrollment closed: FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) - Jun 24, 2014
P1, N=60, Active, not recruiting, Sponsor: University of Illinois at Urbana-Champaign
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
Trial completion: Safety and Tolerability of Glatiramer Acetate (clinicaltrials.gov) - Jun 24, 2014
P3, N=210, Completed, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Rebif (human IFN-?-1a) / EMD Serono
Trial primary completion date, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=306, Active, not recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jul 2015
- || Rebif (human IFN-?-1a) / EMD Serono
Enrollment closed, Trial primary completion date, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=306, Active, not recruiting, Sponsor: EMD Serono
Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- ||||||| insulin peglispro (LY2605541) / Eli Lilly
Trial completion: A Study in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 24, 2014
P3, N=450, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Active, not recruiting --> Completed
- INV103 / Invion
Trial primary completion date: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jun 22, 2014
P1/2, N=32, Recruiting, Sponsor: Invion, Inc.
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Oct 2014
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: SEWORRA: Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 19, 2014
P4, N=30, Recruiting, Sponsor: University Hospital, Rouen
Trial primary completion date: Jul 2014 --> Oct 2014 Trial primary completion date: Oct 2013 --> Oct 2014
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=500, Recruiting, Sponsor: UCB, Inc.
Trial primary completion date: Oct 2013 --> Oct 2014 Trial primary completion date: Sep 2017 --> Dec 2020
- Trial initiation date: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jun 19, 2014
P2, N=80, Not yet recruiting, Sponsor: Academic MS Center Limburg
Trial primary completion date: Sep 2017 --> Dec 2020 Initiation date: May 2014 --> Aug 2014
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
New P3 trial: A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jun 19, 2014
P3, N=490, Recruiting, Sponsor: Samsung Bioepis Co., Ltd.
- | dalfampridine / Generic mfg.
New P2 trial: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jun 19, 2014
P2, N=25, Recruiting, Sponsor: Johns Hopkins University
- ||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Enrollment closed: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jun 19, 2014
P2, N=180, Active, not recruiting, Sponsor: Opexa Therapeutics, Inc.
Initiation date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., cyclosporine / Generic mfg.
Trial primary completion date: Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=22, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2018
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Trial primary completion date: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jun 19, 2014
P2, N=5, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2014 --> Dec 2018 Trial primary completion date: Aug 2013 --> Nov 2011
- Remicade (infliximab) / J&J
Enrollment change, Immune cell: A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Aug 2013 --> Nov 2011 N=30 --> 0
- insulin peglispro (LY2605541) / Eli Lilly
Enrollment open: A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements (clinicaltrials.gov) - Jun 19, 2014
P1, N=28, Recruiting, Sponsor: Eli Lilly and Company
N=30 --> 0 Not yet recruiting --> Recruiting
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Trial completion: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jun 19, 2014
P2, N=5, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: BHYRRA: Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity. (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Jun 2016
- Trial primary completion date: Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes. (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=30, Recruiting, Sponsor: Yale University
Trial primary completion date: Sep 2016 --> Jun 2016 Trial primary completion date: Dec 2014 --> Aug 2014
- Enrollment open: APPEL4: Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=12, Recruiting, Sponsor: J.H. DeVries
Trial primary completion date: Dec 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2014
P1, N=46, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=64, Completed, Sponsor: Jinyang Li
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- ||| sifalimumab (MDX-1103) / AstraZeneca
Enrollment change: A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Subjects With Systemic Lupus Erythematosus or Myositis (clinicaltrials.gov) - Jun 17, 2014
P1/2, N=260, Active, not recruiting, Sponsor: MedImmune LLC
Enrolling by invitation --> Completed N=103 --> 260
- Biomarker, Trial primary completion date: IMMADIAB: Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=100, Recruiting, Sponsor: Assistance Publique - H
N=103 --> 260 Trial primary completion date: May 2015 --> Jun 2016
- || Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? (clinicaltrials.gov) - Jun 17, 2014
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- Enrollment open, HEOR: Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=50, Recruiting, Sponsor: Philippe Klee
Trial primary completion date: May 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- |||| Orencia (abatacept) / BMS
Trial primary completion date, Combination therapy, Monotherapy: AVERT: Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis (clinicaltrials.gov) - Jun 13, 2014
P3, N=348, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Feb 2015
- Trial primary completion date: Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Lahey Clinic
Trial primary completion date: Sep 2014 --> Feb 2015 Trial primary completion date: Oct 2013 --> Sep 2014
- ||||| Orencia (abatacept) / BMS
Trial initiation date, Combination therapy, Monotherapy: AVERT: Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis (clinicaltrials.gov) - Jun 13, 2014
P3, N=348, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2013 --> Sep 2014 Initiation date: Dec 2010 --> Aug 2010
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=6503, Active, not recruiting, Sponsor: Biogen Idec
Initiation date: Dec 2010 --> Aug 2010 N=2000 --> 6503
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: TYGRIS: TYSABRI Global Observational Program in Safety (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=2207, Active, not recruiting, Sponsor: Biogen Idec
N=2000 --> 6503 N=3000 --> 2207
- ||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 13, 2014
P2/3, N=106, Completed, Sponsor: Biogen Idec
N=3000 --> 2207 Recruiting --> Completed
- |||| Cosentyx (secukinumab) / Novartis
Trial completion: Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate (clinicaltrials.gov) - Jun 13, 2014
P2, N=221, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Jun 13, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Nov 2014
- || Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change: Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - Jun 13, 2014
P1, N=55, Completed, Sponsor: Biogen Idec
Trial primary completion date: Feb 2015 --> Nov 2014 N=30 --> 55
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: CAMEO: Canadian Methotrexate and Etanercept Outcome Study (clinicaltrials.gov) - Jun 13, 2014
P4, N=258, Completed, Sponsor: Amgen
N=30 --> 55 Phase classification: P=N/A --> P4
- Enrollment open: CL4M-Controls: Improving Postprandial Glycaemia by a New Developed Closed-loop Control System - Closedloop4meals (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Fundaci
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Phase classification: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jun 12, 2014
P1, N=10, Recruiting, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Phase classification: P2 --> P1
- azithromycin / Generic mfg.
Biomarker, Phase classification: A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin (clinicaltrials.gov) - Jun 12, 2014
P1, N=20, Completed, Sponsor: GlaxoSmithKline
Phase classification: P2 --> P1 Phase classification: P=N/A --> P1
- Trial primary completion date: Reducing Depressive Symptoms in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: University of Pittsburgh
Phase classification: P=N/A --> P1 Trial primary completion date: Jan 2014 --> Jun 2015
- bortezomib / Generic mfg.
Trial primary completion date: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Jun 12, 2014
P4, N=10, Recruiting, Sponsor: The Rogosin Institute
Trial primary completion date: Jan 2014 --> Jun 2015 Trial primary completion date: Jul 2014 --> Jul 2015